Qu Meiyu, He Qiangqiang, Bao Hangyang, Ji Xing, Shen Tingyu, Barkat Muhammad Qasim, Wu Ximei, Zeng Ling-Hui
Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, 030001, China.
Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, 310058, China.
J Pharm Anal. 2024 Aug;14(8):100957. doi: 10.1016/j.jpha.2024.02.011. Epub 2024 Feb 24.
Arsenic compounds are widely used for the therapeutic intervention of multiple diseases. Ancient pharmacologists discovered the medicinal utility of these highly toxic substances, and modern pharmacologists have further recognized the specific active ingredients in human diseases. In particular, Arsenic trioxide (ATO), as a main component, has therapeutic effects on various tumors (including leukemia, hepatocellular carcinoma, lung cancer, etc.). However, its toxicity limits its efficacy, and controlling the toxicity has been an important issue. Interestingly, recent evidence has pointed out the pivotal roles of arsenic compounds in phase separation and membraneless organelles formation, which may determine their toxicity and therapeutic efficacy. Here, we summarize the arsenic compounds-regulating phase separation and membraneless organelles formation. We further hypothesize their potential involvement in the therapy and toxicity of arsenic compounds, highlighting potential mechanisms underlying the clinical application of arsenic compounds.
砷化合物被广泛用于多种疾病的治疗干预。古代药理学家发现了这些剧毒物质的药用价值,现代药理学家则进一步认识到其在人类疾病中的特定活性成分。特别是,三氧化二砷(ATO)作为主要成分,对各种肿瘤(包括白血病、肝细胞癌、肺癌等)具有治疗作用。然而,其毒性限制了其疗效,控制毒性一直是一个重要问题。有趣的是,最近的证据指出了砷化合物在相分离和无膜细胞器形成中的关键作用,这可能决定了它们的毒性和治疗效果。在这里,我们总结了砷化合物对相分离和无膜细胞器形成的调节作用。我们进一步推测它们可能参与砷化合物的治疗和毒性作用,突出了砷化合物临床应用的潜在机制。